Aurora Cannabis Receives Lenders' Consent for Proposed Acquisition of ICC Milestone towards Completing Transaction to Establish Leadership in South American Market EDMONTON and VANCOUVER

Aurora Cannabis Receives Lenders' Consent

for Proposed Acquisition of ICC

Milestone towards Completing

Transaction to Establish Leadership in South American Market

EDMONTON and VANCOUVER, Nov. 1, 2018 /CNW/

- Aurora Cannabis Inc. (Aurora) (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) and ICC Labs Inc. (ICC) (TSX-V:

ICC) are pleased to announce that Aurora has received, from its consortium of lenders led by Bank of Montreal (collectively, the

Lenders), consent and approval as required under its credit agreement with the Lenders to the previously announced plan

of arrangement (the Arrangement) between ICC and Aurora. Subject to the terms and conditions of the arrangement agreement

dated September 8, 2018 (the Arrangement Agreement), Aurora will acquire all of the issued and outstanding common shares

(ICC Shares) of ICC. Obtaining such consent and approval is one of the conditions to completing the Arrangement.

The Arrangement, once approved, will create

a strong foundation for expansion, and will leverage ICC's first-mover advantage in South America, bringing significant low-cost

production capacity, a well-diversified product portfolio, and extensive distribution channels throughout South America and internationally.

Led by CEO Alejandro Antalich, a widely-recognized

leader in the South American cannabis market with over 25 years of experience in the pharmaceutical sector, the acquisition of

ICC will establish Aurora as the industry leader in South America, a continent with over 420 million people. ICC is based

in Uruguay, the first country in the world to legalize cannabis for adult consumer use. In addition, ICC holds licenses in

Colombia for the production of medical cannabis.

Special Meeting of ICC Shareholders

A special meeting (the Meeting) of holders

of ICC Shares (ICC Shareholders) will be held on Tuesday November 6, 2018 at 9:00 a.m. (Toronto time) at Norton Rose Fulbright

Canada LLP, located at Royal Bank Plaza, South Tower, Suite 3800, 200 Bay Street, Toronto. At the Meeting, ICC Shareholders will

be asked to consider and vote on a special resolution (the Arrangement Resolution) approving the Arrangement.

Full details of the Arrangement and certain

other matters are set out in the management information circular of ICC dated October 3, 2018 (as updated by the news release of

ICC dated October 15, 2018) (the Circular). A copy of the Circular and other meeting materials can be found under ICC's

profile on SEDAR at www.sedar.com.

ICC Board Recommendation

ICC's board of directors has unanimously

approved the Arrangement and recommends that ICC Shareholders vote FOR the Arrangement Resolution.

Timing and Conditions

Assuming approval of the Arrangement at the

Meeting, ICC will, on or about November 8, 2018, return to the Supreme Court of British Columbia to seek a final order to implement

the Arrangement. The closing of the Arrangement remains subject to receipt of certain other approvals (including certain Uruguayan

regulatory approvals) and the satisfaction or waiver of certain other customary closing conditions. Approval by shareholders of

Aurora is not required. Assuming all conditions are satisfied, ICC and Aurora expect that the closing of the Arrangement will be

completed in the fourth quarter of 2018.

ICC has retained Laurel Hill Advisory Group

to solicit proxies, on behalf of management, to vote FOR the Arrangement Resolution. If you have any questions relating to your

vote, please contact Laurel Hill by telephone toll free at 1-877-452-7184 (1-416-304-0211 by collect call) or by email at assistance@laurelhill.com.

Headquartered in Edmonton, Alberta, Canada

with funded capacity in excess of 500,000 kg per annum and sales and operations in 19 countries across five continents, Aurora

is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across

every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis

and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora

has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate

leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale

production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are

designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.

Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf

Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to Aurora's rapid organic growth

and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf, CanvasRX,

Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,

Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and the pending acquisition of ICC - Aurora is distinguished

by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic

partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:

HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private),

Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and

NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit

our investor website, investor.auroramj.com

ICC is a fully licensed producer and distributor

of medicinal cannabinoid extracts, recreational cannabis and industrial hemp products in Uruguay as well as a fully licensed producer

of medicinal cannabis in Colombia. ICC has active operations in Uruguay, and is focused on becoming the worldwide leading producer

of cannabinoid extracts, giving support and promoting responsible use for medicinal purposes, backed by scientific research and

innovation, while following strict compliance with standards for quality and safety.

Neither the TSX, TSX-V nor their Regulation

Services Provider (as that term is defined in the policies of the TSX and TSX-V) accepts responsibility for the adequacy or accuracy

Alejandro Antalich, CEO

Aurora Cannabis Inc.

Caution Concerning Forward-Looking Statements

This news release includes statements containing

certain "forward-looking information" within the meaning of applicable securities law (forward-looking statements). Forward-looking

statements are frequently characterized by words such as "plan", "continue", "expect", "project",

"intend", "believe", "anticipate", "estimate", "may", "will", "potential",

"proposed" and other similar words, or statements that certain events or conditions "may" or "will"

occur. Forward-looking statements in this news release include, but are not limited to statements with respect to: the anticipated

timing of the Meeting and the closing of the Arrangement; the satisfaction of closing conditions including required ICC Shareholder

approval; necessary court approvals; the requisite Uruguayan regulatory approvals being obtained; certain other customary closing

conditions; and the expected benefits of the Arrangement.

Implicit in the forward-looking statements

referred to above are assumptions regarding, among other things: the ability of the parties to receive, in a timely manner and

on satisfactory terms, the necessary ICC Shareholder approval and regulatory, court, stock exchange and other third party approvals;

the ability of the parties to satisfy, in a timely manner, the conditions to the closing of the Arrangement; and other expectations

and assumptions concerning the Arrangement. The anticipated timing provided herein in connection with the Arrangement may change

for a number of reasons, including the inability to secure necessary ICC Shareholder approval and regulatory, court, stock exchange

or other third party approvals in the time assumed or the need for additional time to satisfy the other conditions necessary to

complete the Arrangement. ICC Shareholders are urged to carefully read the Circular (as updated by the news release of ICC dated

October 15, 2018) in its entirety.

Forward-looking statements are based on the

opinions and estimates of management of ICC and Aurora at the date the statements are made, and are subject to a variety of risks

and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the

forward-looking statement, whether expressed or implied, including, without limitation: the potential risk that the Arrangement

Resolution will not be approved by ICC Shareholders or that the Arrangement Agreement could be terminated in certain circumstances;

failure to, in a timely manner, or at all, obtain the required regulatory, court, stock exchange or other third party approvals

for the Arrangement or any ancillary transaction; failure of the parties to otherwise satisfy the conditions to complete the Arrangement;